<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MEDI</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28207527</article-id><article-id pub-id-type="pmc">5319516</article-id><article-id pub-id-type="publisher-id">MD-D-16-05652</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000006104</article-id><article-id pub-id-type="art-access-id">06104</article-id><article-categories><subj-group subj-group-type="heading"><subject>3700</subject></subj-group><subj-group><subject>Research Article</subject><subject>Clinical Trial/Experimental Study</subject></subj-group></article-categories><title-group><article-title>Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yuhong</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Ran</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Wang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qiong</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Yuan</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Shuiping</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Danyan</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref rid="cor1" ref-type="corresp"><sup>∗</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Leischik.</surname><given-names>Roman</given-names></name></contrib></contrib-group><aff id="aff1"><label>a</label>Internal Cardiovascular Medicine, Second Xiangya Hospital of Central South University, Changsha, Hunan</aff><aff id="aff2"><label>b</label>Affiliated Peace Changzhi Medical College Hospital, Changzhi, Shanxi, China.</aff><author-notes id="cor1"><corresp><label>∗</label>Correspondence: Danyan Xu, Internal Cardiovascular Medicine, Second Xiangya Hospital of Central South University, Changsha, 410399 Hunan, China (e-mail: <email>cgdzhaoyuhong@163.com</email>).</corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2017</year></pub-date><volume>96</volume><issue>7</issue><elocation-id>e6104</elocation-id><history><date date-type="received"><day>7</day><month>9</month><year>2016</year></date><date date-type="rev-recd"><day>9</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="medi-96-e6104.pdf"></self-uri><abstract><title><offsets xml_i="4628" xml_f="4636" txt_i="11" txt_f="19">Abstract</offsets></title><sec sec-type="background"><title><offsets xml_i="4678" xml_f="4689" txt_i="20" txt_f="31">Background:</offsets></title><p><offsets xml_i="4700" xml_f="5052" txt_i="32" txt_f="384">Atorvastatin decreases blood lipids but is associated with side effects. Zhibitai is a traditional Chinese medicine used to treat blood lipid disorders. The objective of this study is to evaluate the lipid-lowering effect, antiinflammatory effect, and adverse events of zhibitai combined to atorvastatin in patients with coronary heart diseases (CHDs).</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="5093" xml_f="5101" txt_i="386" txt_f="394">Methods:</offsets></title><p><offsets xml_i="5112" xml_f="5498" txt_i="395" txt_f="781">Patients with CHD (n = 150) were randomized to: zhibitai 480 mg + atorvastatin 10 mg (ZA10 group), atorvastatin 20 mg (A20 group), and atorvastatin 40 mg (A40 group). Lipid profile, cardiotrophin-1 (CT-1), and C-reactive protein (CRP) were measured after 4 and 8 weeks of treatment. Self-reported side effects, liver function, kidney function, and creatine kinase levels were monitored.</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="5539" xml_f="5547" txt_i="783" txt_f="791">Results:</offsets></title><p><offsets xml_i="5558" xml_f="5657" txt_i="792" txt_f="891">After 8 weeks, triglycerides, total cholesterol (TC), LDL-cholesterol (LDL-C), and apolipoprotein B</offsets><sub><offsets xml_i="5662" xml_f="5665" txt_i="891" txt_f="894">100</offsets></sub><offsets xml_i="5671" xml_f="5677" txt_i="894" txt_f="900"> (ApoB</offsets><sub><offsets xml_i="5682" xml_f="5685" txt_i="900" txt_f="903">100</offsets></sub><offsets xml_i="5691" xml_f="5859" txt_i="903" txt_f="1071">) levels were decreased in the ZA10 group (−64%, −37%, −46%, and −54%, respectively, compared with baseline), and these changes were similar to those of the A40 group (</offsets><italic><offsets xml_i="5867" xml_f="5868" txt_i="1071" txt_f="1072">P</offsets></italic><offsets xml_i="5877" xml_f="6070" txt_i="1072" txt_f="1262"> &gt; 0.05). CT-1 and high sensitivity-C reactive protein (hs-CRP) levels were significantly decreased in the ZA10 group after 4 and 8 weeks (4 weeks: −73% and 96%; 8 weeks: −89% and −98%; all </offsets><italic><offsets xml_i="6078" xml_f="6079" txt_i="1262" txt_f="1263">P</offsets></italic><offsets xml_i="6088" xml_f="6089" txt_i="1263" txt_f="1264"> </offsets><italic><offsets xml_i="6097" xml_f="6101" txt_i="1264" txt_f="1265">&lt;</offsets></italic><offsets xml_i="6110" xml_f="6158" txt_i="1265" txt_f="1313"> 0.01), without differences among the 3 groups (</offsets><italic><offsets xml_i="6166" xml_f="6167" txt_i="1313" txt_f="1314">P</offsets></italic><offsets xml_i="6176" xml_f="6367" txt_i="1314" txt_f="1502"> &gt; 0.05). After 8 weeks of treatment, adverse events (abdominal distention, nausea, vomiting, and hunger) were found in 4, 5, and 7 patients in the ZA10, A20, and A40 groups, respectively.</offsets></p></sec><sec sec-type="conclusion"><title><offsets xml_i="6411" xml_f="6422" txt_i="1504" txt_f="1515">Conclusion:</offsets></title><p><offsets xml_i="6433" xml_f="6615" txt_i="1516" txt_f="1698">ZA10 significantly reduced triglycerides, TC, LDL-C, ApoB, CT-1, and hs-CRP levels in patients with CHD, similar to the effects of A40 and A20, but ZA10 lead to fewer adverse events.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>atorvastatin</kwd><kwd>cardiotrophin-1</kwd><kwd>cholesterol</kwd><kwd>high sensitive-C reactive protein</kwd><kwd>zhibitai</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><label><offsets xml_i="6986" xml_f="6987" txt_i="1707" txt_f="1708">1</offsets></label><title><offsets xml_i="7002" xml_f="7014" txt_i="1708" txt_f="1720">Introduction</offsets></title><p><offsets xml_i="7025" xml_f="7252" txt_i="1721" txt_f="1948">Health is the most important construct of our life. The 21st century enabled us to live in improved living conditions. However, although our health status changed, many chronic stages of diseases were integrated into our lives.</offsets><sup><offsets xml_i="7257" xml_f="7258" txt_i="1948" txt_f="1949">[</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="7289" xml_f="7290" txt_i="1949" txt_f="1950">1</offsets></xref><offsets xml_i="7297" xml_f="7298" txt_i="1950" txt_f="1951">]</offsets></sup><offsets xml_i="7304" xml_f="7383" txt_i="1951" txt_f="2030"> Physical inactivity is one of the risk factors of atherosclerosis and obesity,</offsets><sup><offsets xml_i="7388" xml_f="7389" txt_i="2030" txt_f="2031">[</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="7420" xml_f="7421" txt_i="2031" txt_f="2032">2</offsets></xref><offsets xml_i="7428" xml_f="7429" txt_i="2032" txt_f="2033">]</offsets></sup><offsets xml_i="7435" xml_f="7751" txt_i="2033" txt_f="2349"> and may even be the most important. There is now overwhelming evidence that regular physical activity has important and wide-ranging health benefits. These range from reduced risk of chronic diseases such as heart disease, type 2 diabetes, and some cancers to enhance function and preservation of function with age.</offsets><sup><offsets xml_i="7756" xml_f="7757" txt_i="2349" txt_f="2350">[</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="7788" xml_f="7789" txt_i="2350" txt_f="2351">3</offsets></xref><offsets xml_i="7796" xml_f="7797" txt_i="2351" txt_f="2352">]</offsets></sup><offsets xml_i="7803" xml_f="7904" txt_i="2352" txt_f="2453"> Existing research shows that proper physical exercise, a healthy environment and balanced nutrition,</offsets><sup><offsets xml_i="7909" xml_f="7910" txt_i="2453" txt_f="2454">[</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="7941" xml_f="7942" txt_i="2454" txt_f="2455">4</offsets></xref><offsets xml_i="7949" xml_f="7950" txt_i="2455" txt_f="2456">]</offsets></sup><offsets xml_i="7956" xml_f="8054" txt_i="2456" txt_f="2554"> and good state of mind is an effective factor for the prevention of coronary heart disease (CHD).</offsets></p><p><offsets xml_i="8061" xml_f="8245" txt_i="2555" txt_f="2739">Atherosclerosis leads to the narrowing of the lumen of coronary arteries. Eventually, progressive plaque thickening and/or rupture may lead to angina and/or myocardial infarction (MI).</offsets><sup><offsets xml_i="8250" xml_f="8251" txt_i="2739" txt_f="2740">[</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="8282" xml_f="8283" txt_i="2740" txt_f="2741">5</offsets></xref><offsets xml_i="8290" xml_f="8291" txt_i="2741" txt_f="2742">–</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="8322" xml_f="8323" txt_i="2742" txt_f="2743">8</offsets></xref><offsets xml_i="8330" xml_f="8331" txt_i="2743" txt_f="2744">]</offsets></sup><offsets xml_i="8337" xml_f="8420" txt_i="2744" txt_f="2827"> In the United States, the prevalence of CHD is about 6.2% in people ≥20 years old.</offsets><sup><offsets xml_i="8425" xml_f="8426" txt_i="2827" txt_f="2828">[</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="8457" xml_f="8458" txt_i="2828" txt_f="2829">9</offsets></xref><offsets xml_i="8465" xml_f="8466" txt_i="2829" txt_f="2830">]</offsets></sup><offsets xml_i="8472" xml_f="8578" txt_i="2830" txt_f="2936"> The rates of major cardiovascular events are higher in developing countries compared with developed ones.</offsets><sup><offsets xml_i="8583" xml_f="8584" txt_i="2936" txt_f="2937">[</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="8616" xml_f="8618" txt_i="2937" txt_f="2939">10</offsets></xref><offsets xml_i="8625" xml_f="8626" txt_i="2939" txt_f="2940">]</offsets></sup><offsets xml_i="8632" xml_f="8758" txt_i="2940" txt_f="3066"> Mortality from ischemic heart disease is the leading cause of mortality worldwide, with 12.7% of the total mortality in 2008.</offsets><sup><offsets xml_i="8763" xml_f="8764" txt_i="3066" txt_f="3067">[</offsets><xref rid="R11" ref-type="bibr"><offsets xml_i="8796" xml_f="8798" txt_i="3067" txt_f="3069">11</offsets></xref><offsets xml_i="8805" xml_f="8806" txt_i="3069" txt_f="3070">]</offsets></sup><offsets xml_i="8812" xml_f="8906" txt_i="3070" txt_f="3164"> Hyperlipidemia is a major risk factor for the development and progression of atherosclerosis.</offsets><sup><offsets xml_i="8911" xml_f="8912" txt_i="3164" txt_f="3165">[</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="8943" xml_f="8944" txt_i="3165" txt_f="3166">5</offsets></xref><offsets xml_i="8951" xml_f="8952" txt_i="3166" txt_f="3167">–</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="8983" xml_f="8984" txt_i="3167" txt_f="3168">8</offsets></xref><offsets xml_i="8991" xml_f="8992" txt_i="3168" txt_f="3169">]</offsets></sup></p><p><offsets xml_i="9005" xml_f="9157" txt_i="3170" txt_f="3322">Statins are 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors; this enzyme normally catalyzes the rate-limiting step of cholesterol synthesis.</offsets><sup><offsets xml_i="9162" xml_f="9163" txt_i="3322" txt_f="3323">[</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="9195" xml_f="9197" txt_i="3323" txt_f="3325">12</offsets></xref><offsets xml_i="9204" xml_f="9205" txt_i="3325" txt_f="3326">]</offsets></sup><offsets xml_i="9211" xml_f="9414" txt_i="3326" txt_f="3529"> Therefore, statins induce cholesterol depletion within the hepatocytes, leading to the upregulation of the low-density lipoprotein (LDL) receptor in order to obtain cholesterol from blood LDL particles.</offsets><sup><offsets xml_i="9419" xml_f="9420" txt_i="3529" txt_f="3530">[</offsets><xref rid="R13" ref-type="bibr"><offsets xml_i="9452" xml_f="9454" txt_i="3530" txt_f="3532">13</offsets></xref><offsets xml_i="9461" xml_f="9462" txt_i="3532" txt_f="3533">]</offsets></sup><offsets xml_i="9468" xml_f="9575" txt_i="3533" txt_f="3640"> Statins also decrease C-reactive protein (CRP) levels, but their effect on inflammation is not consistent.</offsets><sup><offsets xml_i="9580" xml_f="9581" txt_i="3640" txt_f="3641">[</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="9613" xml_f="9615" txt_i="3641" txt_f="3643">14</offsets></xref><offsets xml_i="9622" xml_f="9623" txt_i="3643" txt_f="3644">]</offsets></sup><offsets xml_i="9629" xml_f="9709" txt_i="3644" txt_f="3724"> Statins are the drugs of choice for patients at risk of CHD or CHD progression.</offsets><sup><offsets xml_i="9714" xml_f="9715" txt_i="3724" txt_f="3725">[</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="9747" xml_f="9749" txt_i="3725" txt_f="3727">15</offsets></xref><offsets xml_i="9756" xml_f="9757" txt_i="3727" txt_f="3728">]</offsets></sup><offsets xml_i="9763" xml_f="10106" txt_i="3728" txt_f="4071"> Statins significantly reduce the incidence of all-cause mortality and major coronary events as compared to control in both secondary and primary prevention. Atorvastatin was significantly more effective than pravastatin (OR 0.65, 95% CI 0.43–0.99) and simvastatin (OR 0.68, 95% CI 0.38–0.98) for secondary prevention of major coronary events.</offsets><sup><offsets xml_i="10111" xml_f="10112" txt_i="4071" txt_f="4072">[</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="10144" xml_f="10146" txt_i="4072" txt_f="4074">16</offsets></xref><offsets xml_i="10153" xml_f="10154" txt_i="4074" txt_f="4075">]</offsets></sup><offsets xml_i="10160" xml_f="10250" txt_i="4075" txt_f="4165"> Atorvastatin is a 3rd-generation statin with a good efficacy and adequate safety profile.</offsets><sup><offsets xml_i="10255" xml_f="10256" txt_i="4165" txt_f="4166">[</offsets><xref rid="R17" ref-type="bibr"><offsets xml_i="10288" xml_f="10290" txt_i="4166" txt_f="4168">17</offsets></xref><offsets xml_i="10297" xml_f="10298" txt_i="4168" txt_f="4169">]</offsets></sup></p><p><offsets xml_i="10311" xml_f="10496" txt_i="4170" txt_f="4355">Nevertheless, statins are associated with adverse effects such as myopathy, hepatic toxicity, hyperglycemia, and impaired steroid production; rhabdomyolysis and death are also possible.</offsets><sup><offsets xml_i="10501" xml_f="10502" txt_i="4355" txt_f="4356">[</offsets><xref rid="R18" ref-type="bibr"><offsets xml_i="10534" xml_f="10536" txt_i="4356" txt_f="4358">18</offsets></xref><offsets xml_i="10543" xml_f="10544" txt_i="4358" txt_f="4359">]</offsets></sup><offsets xml_i="10550" xml_f="10611" txt_i="4359" txt_f="4420"> The risk of adverse effects increases with the higher doses.</offsets><sup><offsets xml_i="10616" xml_f="10617" txt_i="4420" txt_f="4421">[</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="10649" xml_f="10651" txt_i="4421" txt_f="4423">19</offsets></xref><offsets xml_i="10658" xml_f="10659" txt_i="4423" txt_f="4424">]</offsets></sup><offsets xml_i="10665" xml_f="11055" txt_i="4424" txt_f="4814"> Statins have been shown to reduce the risk of all-cause mortality among individuals with clinical history of CHD. However, it remains uncertain whether statins have similar mortality benefit in a high-risk primary prevention setting. One literature-based meta-analysis did not find evidence for the benefit of statin therapy on all-cause mortality in a high-risk primary prevention set-up.</offsets><sup><offsets xml_i="11060" xml_f="11061" txt_i="4814" txt_f="4815">[</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="11093" xml_f="11095" txt_i="4815" txt_f="4817">20</offsets></xref><offsets xml_i="11102" xml_f="11103" txt_i="4817" txt_f="4818">]</offsets></sup><offsets xml_i="11109" xml_f="11297" txt_i="4818" txt_f="5006"> The findings suggest that intensive dose atorvastatin therapy does not attenuate the progression of coronary calcification compared with standard dose atorvastatin therapy over 12 months.</offsets><sup><offsets xml_i="11302" xml_f="11303" txt_i="5006" txt_f="5007">[</offsets><xref rid="R21" ref-type="bibr"><offsets xml_i="11335" xml_f="11337" txt_i="5007" txt_f="5009">21</offsets></xref><offsets xml_i="11344" xml_f="11345" txt_i="5009" txt_f="5010">]</offsets></sup></p><p><offsets xml_i="11358" xml_f="11676" txt_i="5011" txt_f="5329">Chinese medicine has been regarded as a kind of complementary therapies in the Western countries. However, it has been one of the mainstream therapies in some Asian countries, such as Taiwan, Korea, and China, including acupuncture, moxibustion, Chinese orthopedics and traumatology, and Chinese herbal medicine (CHM).</offsets><sup><offsets xml_i="11681" xml_f="11682" txt_i="5329" txt_f="5330">[</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="11714" xml_f="11716" txt_i="5330" txt_f="5332">22</offsets></xref><offsets xml_i="11723" xml_f="11724" txt_i="5332" txt_f="5333">]</offsets></sup><offsets xml_i="11730" xml_f="12147" txt_i="5333" txt_f="5750"> CHM has a long history and is widely used in the prevention and treatment of a variety of diseases worldwide. CHM has been used to treat stroke for thousands of years. The findings suggest that bioactive components of CHM may improve neurological function, reduce infarct volume, and promote endogenous neurogenesis, including proliferation, migration, and differentiation of neural stem cells after ischemic stroke.</offsets><sup><offsets xml_i="12152" xml_f="12153" txt_i="5750" txt_f="5751">[</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="12185" xml_f="12187" txt_i="5751" txt_f="5753">23</offsets></xref><offsets xml_i="12194" xml_f="12195" txt_i="5753" txt_f="5754">]</offsets></sup><offsets xml_i="12201" xml_f="12465" txt_i="5754" txt_f="6018"> Zhibitai is a traditional Chinese medicine that is made of naturally occurring statins and it is used to treat blood lipid disorders. Previous studies have shown that zhibitai was comparable to atorvastatin in terms of lipid-lowering and antiinflammatory effects.</offsets><sup><offsets xml_i="12470" xml_f="12471" txt_i="6018" txt_f="6019">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="12503" xml_f="12505" txt_i="6019" txt_f="6021">24</offsets></xref><offsets xml_i="12512" xml_f="12513" txt_i="6021" txt_f="6022">–</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="12545" xml_f="12547" txt_i="6022" txt_f="6024">26</offsets></xref><offsets xml_i="12554" xml_f="12555" txt_i="6024" txt_f="6025">]</offsets></sup><offsets xml_i="12561" xml_f="12651" txt_i="6025" txt_f="6115"> Therefore, zhibitai could be an appropriate alternative to chemical lipid-lowering drugs.</offsets></p><p><offsets xml_i="12658" xml_f="12955" txt_i="6116" txt_f="6413">Therefore, the aim of the present study was to further evaluate the lipid-lowering effect, antiinflammatory effect, and adverse events of zhibitai combined to atorvastatin 10 mg in patients with CHDs, and to investigate the advantages of the combination compared with higher doses of atorvastatin.</offsets></p></sec><sec><label><offsets xml_i="12977" xml_f="12978" txt_i="6415" txt_f="6416">2</offsets></label><title><offsets xml_i="12993" xml_f="13000" txt_i="6416" txt_f="6423">Methods</offsets></title><sec><label><offsets xml_i="13020" xml_f="13023" txt_i="6424" txt_f="6427">2.1</offsets></label><title><offsets xml_i="13038" xml_f="13046" txt_i="6427" txt_f="6435">Patients</offsets></title><p><offsets xml_i="13057" xml_f="13462" txt_i="6436" txt_f="6841">This was a prospective study of patients with CHD treated at the Inpatient and Outpatient Departments of the Second Xiangya Hospital of Central South University and at the Peace Hospital Affiliated to Changzhi Medical College (Shanxi, China) between October 2010 and May 2011. The study was approved by the ethical committees of the 2 participating hospitals. All patients signed an informed consent form.</offsets></p><p><offsets xml_i="13469" xml_f="13869" txt_i="6842" txt_f="7233">The inclusion criteria were: diagnosis of CHD with signs and symptoms of MI (typical chest pains and pain-related ST-T changes; typical chest pains and positive treadmill exercise test; or typical chest pains and coronary angiography showing one or multiple coronary branches with stenosis &gt;50%); &gt;20 but &lt;75 years of age; and volunteered to participate and signed the informed consent form.</offsets></p><p><offsets xml_i="13876" xml_f="14182" txt_i="7234" txt_f="7540">The exclusion criteria were: history of MI during the past 3 months; history of cerebrovascular accidents during the past 6 months; history of severe trauma or major surgery; nephrotic syndrome; hypothyroidism; any liver or gallbladder disorders; familial hypercholesterolemia; or secondary hyperlipidemia.</offsets></p><p><offsets xml_i="14189" xml_f="14504" txt_i="7541" txt_f="7856">The following drugs were allowed: angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, calcium channel blockers, clopidogrel, bayaspirin, and β-receptor blockers, as well as other antiplatelet, anticoagulation, antihypertensive, hypoglycemic, and coronary artery dilation drugs such as syncon.</offsets></p></sec><sec><label><offsets xml_i="14526" xml_f="14529" txt_i="7858" txt_f="7861">2.2</offsets></label><title><offsets xml_i="14544" xml_f="14556" txt_i="7861" txt_f="7873">Study design</offsets></title><p><offsets xml_i="14567" xml_f="14823" txt_i="7874" txt_f="8130">This was a randomized, parallel study. Patients were randomized using a random number table and sealed envelopes prepared by a statistician. Patients in the zhibitai 480 mg + atorvastatin 10 mg (ZA10) group received zhibitai (480 mg, twice daily, batch #WS</offsets><sub><offsets xml_i="14828" xml_f="14829" txt_i="8130" txt_f="8131">3</offsets></sub><offsets xml_i="14835" xml_f="15231" txt_i="8131" txt_f="8527">–119(Z-119)-2004(Z), Chengdu Di’ao Pharmaceutical Group Corporation, China) and atorvastatin (10 mg, once daily Pfizer Pharmaceutical Co., Ltd.) at night for 8 weeks. The patients in the atorvastatin 20 mg (A20) group received 20 mg of atorvastatin once daily at night for 8 weeks. The patients in the atorvastatin 40 mg (A40) group received 40 mg of atorvastatin once daily at night for 8 weeks.</offsets></p></sec><sec><label><offsets xml_i="15253" xml_f="15256" txt_i="8529" txt_f="8532">2.3</offsets></label><title><offsets xml_i="15271" xml_f="15278" txt_i="8532" txt_f="8539">Testing</offsets></title><p><offsets xml_i="15289" xml_f="15689" txt_i="8540" txt_f="8940">Fasting peripheral venous blood was collected in the morning before treatment and after 4 and 8 weeks of treatment. Levels of cardiotrophin-1 (CT-1) (Xinqidi Biological technology Co., Ltd., Wuhan, China), high sensitivity-C reactive protein (hs-CRP, P800, Roche Diagnostics, Germany), triglycerides, total cholesterol (TC), LDL-cholesterol (LDL-C), high-density lipoprotein cholesterol, apoprotein B</offsets><sub><offsets xml_i="15694" xml_f="15697" txt_i="8940" txt_f="8943">100</offsets></sub><offsets xml_i="15703" xml_f="15709" txt_i="8943" txt_f="8949"> (ApoB</offsets><sub><offsets xml_i="15714" xml_f="15717" txt_i="8949" txt_f="8952">100</offsets></sub><offsets xml_i="15723" xml_f="15731" txt_i="8952" txt_f="8960">), apo A</offsets><sub><offsets xml_i="15736" xml_f="15737" txt_i="8960" txt_f="8961">1</offsets></sub><offsets xml_i="15743" xml_f="15950" txt_i="8961" txt_f="9168">, creatine kinase, and markers of liver and renal functions were detected using DXI800 and AU5800 automatic biochemical analyzers (Beckman, United States of America). Twelve-lead ECG was performed routinely.</offsets></p></sec><sec><label><offsets xml_i="15972" xml_f="15975" txt_i="9170" txt_f="9173">2.4</offsets></label><title><offsets xml_i="15990" xml_f="16010" txt_i="9173" txt_f="9193">Statistical analyses</offsets></title><p><offsets xml_i="16021" xml_f="16059" txt_i="9194" txt_f="9232">Based on previous studies of zhibitai,</offsets><sup><offsets xml_i="16064" xml_f="16065" txt_i="9232" txt_f="9233">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="16097" xml_f="16099" txt_i="9233" txt_f="9235">24</offsets></xref><offsets xml_i="16106" xml_f="16107" txt_i="9235" txt_f="9236">–</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="16139" xml_f="16141" txt_i="9236" txt_f="9238">26</offsets></xref><offsets xml_i="16148" xml_f="16149" txt_i="9238" txt_f="9239">]</offsets></sup><offsets xml_i="16155" xml_f="16433" txt_i="9239" txt_f="9517"> it was determined that a sample size of 35 per group was necessary to detect a difference at a power of 80% and α = 0.05. SPSS 16.0 (IBM, Armonk, NY) was used for statistical analysis. Continuous data were presented as means ± standard deviation and analyzed using independent </offsets><italic><offsets xml_i="16441" xml_f="16443" txt_i="9517" txt_f="9519">t-</offsets></italic><offsets xml_i="16452" xml_f="16501" txt_i="9519" txt_f="9568">tests for comparisons between 2 groups or paired </offsets><italic><offsets xml_i="16509" xml_f="16511" txt_i="9568" txt_f="9570">t-</offsets></italic><offsets xml_i="16520" xml_f="16807" txt_i="9570" txt_f="9857">tests for comparisons before/after treatment. One-way analysis of variance was used for comparison among the 3 groups, with the Tukey post hoc test. Categorical data were presented using frequencies and percentages and analyzed using the chi-square test. All analyses were two-sided and </offsets><italic><offsets xml_i="16815" xml_f="16816" txt_i="9857" txt_f="9858">P</offsets></italic><offsets xml_i="16825" xml_f="16884" txt_i="9858" txt_f="9914">-values &lt;0.05 were considered statistically significant.</offsets></p></sec></sec><sec><label><offsets xml_i="16912" xml_f="16913" txt_i="9917" txt_f="9918">3</offsets></label><title><offsets xml_i="16928" xml_f="16935" txt_i="9918" txt_f="9925">Results</offsets></title><sec><label><offsets xml_i="16955" xml_f="16958" txt_i="9926" txt_f="9929">3.1</offsets></label><title><offsets xml_i="16973" xml_f="17004" txt_i="9929" txt_f="9960">Characteristics of the patients</offsets></title><p><offsets xml_i="17015" xml_f="17405" txt_i="9961" txt_f="10351">A total of 150 patients were randomized (n = 50/group). 1 patient in the ZA10 group was lost to follow-up and 1 patient was excluded because of poor compliance. 2 and 3 patients in the A20 and A40 groups, respectively, were excluded because of poor compliance. Therefore, 48, 48, and 47 patients in the ZA10, A20, and A40 groups, respectively, were included in for the statistical analysis.</offsets></p><p><offsets xml_i="17412" xml_f="17655" txt_i="10352" txt_f="10595">There were no significant differences in age, sex, body mass index, smoking history, liver function, renal function, blood lipids, creatine kinase, blood pressure, diabetes, family history of CHD, and drugs among the 3 groups at baseline (all </offsets><italic><offsets xml_i="17663" xml_f="17664" txt_i="10595" txt_f="10596">P</offsets></italic><offsets xml_i="17673" xml_f="17692" txt_i="10596" txt_f="10612"> &gt; 0.05) (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="17724" xml_f="17725" txt_i="10612" txt_f="10613">1</offsets></xref><offsets xml_i="17732" xml_f="17734" txt_i="10613" txt_f="10615">).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="17782" xml_f="17789" txt_i="10616" txt_f="10623">Table 1</offsets></label><caption><p><offsets xml_i="17809" xml_f="17845" txt_i="10623" txt_f="10659">Characteristics of the CHD patients.</offsets></p></caption><graphic xlink:href="medi-96-e6104-g001"></graphic></table-wrap></sec><sec><label><offsets xml_i="17941" xml_f="17944" txt_i="10661" txt_f="10664">3.2</offsets></label><title><offsets xml_i="17959" xml_f="17999" txt_i="10664" txt_f="10704">Changes in lipid profile after treatment</offsets></title><p><offsets xml_i="18010" xml_f="18143" txt_i="10705" txt_f="10838">Compared with baseline, blood lipids after 4 and 8 weeks of treatment were significantly changed in all 3 groups. TC, LDL-C, and ApoB</offsets><sub><offsets xml_i="18148" xml_f="18151" txt_i="10838" txt_f="10841">100</offsets></sub><offsets xml_i="18157" xml_f="18211" txt_i="10841" txt_f="10895"> were decreased significantly compared with baseline (</offsets><italic><offsets xml_i="18219" xml_f="18220" txt_i="10895" txt_f="10896">P</offsets></italic><offsets xml_i="18229" xml_f="18300" txt_i="10896" txt_f="10964"> &lt; 0.01), and the resulting levels were similar among all 3 groups (</offsets><italic><offsets xml_i="18308" xml_f="18309" txt_i="10964" txt_f="10965">P</offsets></italic><offsets xml_i="18318" xml_f="18450" txt_i="10965" txt_f="11094"> &gt; 0.05 among groups at 4 and 8 weeks). The decreases in TG levels were significant in the ZA10 and A40 groups at 4 and 8 weeks (</offsets><italic><offsets xml_i="18458" xml_f="18459" txt_i="11094" txt_f="11095">P</offsets></italic><offsets xml_i="18468" xml_f="18556" txt_i="11095" txt_f="11180"> &lt; 0.01), while the decrease in TG in the A20 group was only significant at 8 weeks (</offsets><italic><offsets xml_i="18564" xml_f="18565" txt_i="11180" txt_f="11181">P</offsets></italic><offsets xml_i="18574" xml_f="18657" txt_i="11181" txt_f="11261"> &lt; 0.01). There were no differences in TG levels among the 3 groups at 8 weeks (</offsets><italic><offsets xml_i="18665" xml_f="18666" txt_i="11261" txt_f="11262">P</offsets></italic><offsets xml_i="18675" xml_f="18694" txt_i="11262" txt_f="11278"> &gt; 0.05) (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="18726" xml_f="18727" txt_i="11278" txt_f="11279">2</offsets></xref><offsets xml_i="18734" xml_f="18736" txt_i="11279" txt_f="11281">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="18784" xml_f="18791" txt_i="11282" txt_f="11289">Table 2</offsets></label><caption><p><offsets xml_i="18811" xml_f="18892" txt_i="11289" txt_f="11370">Changes in lipid profile after zhibitai + atorvastatin or atorvastatin treatment.</offsets></p></caption><graphic xlink:href="medi-96-e6104-g002"></graphic></table-wrap></sec><sec><label><offsets xml_i="18988" xml_f="18991" txt_i="11372" txt_f="11375">3.3</offsets></label><title><offsets xml_i="19006" xml_f="19048" txt_i="11375" txt_f="11417">Changes in CT-1 and hs-CRP after treatment</offsets></title><p><offsets xml_i="19059" xml_f="19173" txt_i="11418" txt_f="11532">CT-1 levels were decreased significantly after 4 and 8 weeks of treatment in all 3 groups compared with baseline (</offsets><italic><offsets xml_i="19181" xml_f="19182" txt_i="11532" txt_f="11533">P</offsets></italic><offsets xml_i="19191" xml_f="19262" txt_i="11533" txt_f="11601"> &lt; 0.01), and the resulting levels were similar among all 3 groups (</offsets><italic><offsets xml_i="19270" xml_f="19271" txt_i="11601" txt_f="11602">P</offsets></italic><offsets xml_i="19280" xml_f="19401" txt_i="11602" txt_f="11720"> &gt; 0.05). hs-CRP levels were also decreased significantly after 4 and 8 weeks in the 3 groups compared with baseline (</offsets><italic><offsets xml_i="19409" xml_f="19410" txt_i="11720" txt_f="11721">P</offsets></italic><offsets xml_i="19419" xml_f="19471" txt_i="11721" txt_f="11770"> &lt; 0.05), without difference among the 3 groups (</offsets><italic><offsets xml_i="19479" xml_f="19480" txt_i="11770" txt_f="11771">P</offsets></italic><offsets xml_i="19489" xml_f="19508" txt_i="11771" txt_f="11787"> &gt; 0.05) (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="19540" xml_f="19541" txt_i="11787" txt_f="11788">3</offsets></xref><offsets xml_i="19548" xml_f="19550" txt_i="11788" txt_f="11790">).</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="19598" xml_f="19605" txt_i="11791" txt_f="11798">Table 3</offsets></label><caption><p><offsets xml_i="19625" xml_f="19715" txt_i="11798" txt_f="11888">Changes in CT-1 and hs-CRP levels after zhibitai + atorvastatin or atorvastatin treatment.</offsets></p></caption><graphic xlink:href="medi-96-e6104-g003"></graphic></table-wrap></sec><sec><label><offsets xml_i="19811" xml_f="19814" txt_i="11890" txt_f="11893">3.4</offsets></label><title><offsets xml_i="19829" xml_f="19894" txt_i="11893" txt_f="11958">Liver and renal functions, creatine kinase, and adverse reactions</offsets></title><p><offsets xml_i="19905" xml_f="20319" txt_i="11959" txt_f="12373">After 8 weeks of treatment, adverse events (abdominal distention, nausea, vomiting, and hunger) were reported in 4, 5, and 7 patients in the ZA10, A20, and A40 groups, respectively. Before treatment, and after 4 weeks, 8 weeks treatment, incidence of creatine kinase increasing, the incidence of myopathy, the incidence of gastrointestinal adverse reactions have no significant difference in the three groups (all </offsets><italic><offsets xml_i="20327" xml_f="20328" txt_i="12373" txt_f="12374">P</offsets></italic><offsets xml_i="20337" xml_f="20424" txt_i="12374" txt_f="12458"> &gt; 0.05), and between the each 2 groups, no significant difference can be observed (</offsets><italic><offsets xml_i="20432" xml_f="20433" txt_i="12458" txt_f="12459">P</offsets></italic><offsets xml_i="20442" xml_f="20556" txt_i="12459" txt_f="12570"> &gt; 0.05), There was no significant difference in CK between the three groups before and after treatment (Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="20588" xml_f="20589" txt_i="12570" txt_f="12571">4</offsets></xref><offsets xml_i="20596" xml_f="20598" txt_i="12571" txt_f="12573">).</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="20646" xml_f="20653" txt_i="12574" txt_f="12581">Table 4</offsets></label><caption><p><offsets xml_i="20673" xml_f="20745" txt_i="12581" txt_f="12653">Adverse events during zhibitai + atorvastatin or atorvastatin treatment.</offsets></p></caption><graphic xlink:href="medi-96-e6104-g004"></graphic></table-wrap></sec></sec><sec><label><offsets xml_i="20847" xml_f="20848" txt_i="12656" txt_f="12657">4</offsets></label><title><offsets xml_i="20863" xml_f="20873" txt_i="12657" txt_f="12667">Discussion</offsets></title><p><offsets xml_i="20884" xml_f="21050" txt_i="12668" txt_f="12834">Abnormal lipid metabolism is a major cause and an independent risk factor of CHD. Therefore, lipid-lowering therapy is crucial to the treatment and prevention of CHD.</offsets><sup><offsets xml_i="21055" xml_f="21056" txt_i="12834" txt_f="12835">[</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="21088" xml_f="21090" txt_i="12835" txt_f="12837">27</offsets></xref><offsets xml_i="21097" xml_f="21098" txt_i="12837" txt_f="12838">,</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="21130" xml_f="21132" txt_i="12838" txt_f="12840">28</offsets></xref><offsets xml_i="21139" xml_f="21140" txt_i="12840" txt_f="12841">]</offsets></sup><offsets xml_i="21146" xml_f="21212" txt_i="12841" txt_f="12907"> Statins are the main currently accepted lipid-lowering treatment.</offsets><sup><offsets xml_i="21217" xml_f="21218" txt_i="12907" txt_f="12908">[</offsets><xref rid="R13" ref-type="bibr"><offsets xml_i="21250" xml_f="21252" txt_i="12908" txt_f="12910">13</offsets></xref><offsets xml_i="21259" xml_f="21260" txt_i="12910" txt_f="12911">–</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="21292" xml_f="21294" txt_i="12911" txt_f="12913">15</offsets></xref><offsets xml_i="21301" xml_f="21302" txt_i="12913" txt_f="12914">]</offsets></sup><offsets xml_i="21308" xml_f="21486" txt_i="12914" txt_f="13092"> However, most intensive lipid-lowering studies tried to achieve better clinical efficacy by increasing the doses of statins, which led to increased incidence of adverse effects.</offsets><sup><offsets xml_i="21491" xml_f="21492" txt_i="13092" txt_f="13093">[</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="21524" xml_f="21526" txt_i="13093" txt_f="13095">19</offsets></xref><offsets xml_i="21533" xml_f="21534" txt_i="13095" txt_f="13096">]</offsets></sup></p><p><offsets xml_i="21547" xml_f="21786" txt_i="13097" txt_f="13336">Therefore, the aim of the present study was to evaluate the lipid-lowering effect, antiinflammatory effect, and adverse events of zhibitai combined to atorvastatin 10 mg in patients with CHD. The results showed that TG, TC, LDL-C, and ApoB</offsets><sub><offsets xml_i="21791" xml_f="21794" txt_i="13336" txt_f="13339">100</offsets></sub><offsets xml_i="21800" xml_f="22171" txt_i="13339" txt_f="13710"> levels were decreased in the ZA10 group to a similar extent than in the A40 group. The levels of CT-1 and hs-CRP were significantly decreased in the ZA10 group after 4 and 8 weeks, without difference among the 3 groups. The incidence of adverse events (abdominal distention, nausea, vomiting, and hunger) in the ZA10 group was lower compared with the A20 and A40 groups.</offsets></p><p><offsets xml_i="22178" xml_f="22309" txt_i="13711" txt_f="13842">Previous studies have shown that zhibitai used alone could lower blood lipids and inflammatory factors (including hs-CRP and CT-1).</offsets><sup><offsets xml_i="22314" xml_f="22315" txt_i="13842" txt_f="13843">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="22347" xml_f="22349" txt_i="13843" txt_f="13845">24</offsets></xref><offsets xml_i="22356" xml_f="22357" txt_i="13845" txt_f="13846">–</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="22389" xml_f="22391" txt_i="13846" txt_f="13848">26</offsets></xref><offsets xml_i="22398" xml_f="22399" txt_i="13848" txt_f="13849">]</offsets></sup><offsets xml_i="22405" xml_f="22798" txt_i="13849" txt_f="14242"> The present study showed that the combined use of zhibitai and atorvastatin 10 mg could achieve a clinical efficacy comparable to that of higher doses of atorvastatin, without additional adverse effects. In the present study, the extent of TG lowering was higher than that of TC lowering when using zhibitai. As the majority of Asian patients with hyperlipidemia are mainly with increased TG,</offsets><sup><offsets xml_i="22803" xml_f="22804" txt_i="14242" txt_f="14243">[</offsets><xref rid="R29" ref-type="bibr"><offsets xml_i="22836" xml_f="22838" txt_i="14243" txt_f="14245">29</offsets></xref><offsets xml_i="22845" xml_f="22846" txt_i="14245" txt_f="14246">]</offsets></sup><offsets xml_i="22852" xml_f="23147" txt_i="14246" txt_f="14541"> zhibitai could be more appropriate for patients with mixed hyperlipidemia characterized by increased TG. In addition, zhibitai combined to atorvastatin could achieve even better lipid-lowering effects. Therefore, technically, zhibitai could be suitable for Chinese patients with hyperlipidemia.</offsets></p><p><offsets xml_i="23154" xml_f="23313" txt_i="14542" txt_f="14701">Recent studies have shown that increased serum hs-CRP levels are closely associated with CHD and can be used to evaluate the patients’ condition and stability.</offsets><sup><offsets xml_i="23318" xml_f="23319" txt_i="14701" txt_f="14702">[</offsets><xref rid="R30" ref-type="bibr"><offsets xml_i="23351" xml_f="23353" txt_i="14702" txt_f="14704">30</offsets></xref><offsets xml_i="23360" xml_f="23361" txt_i="14704" txt_f="14705">–</offsets><xref rid="R32" ref-type="bibr"><offsets xml_i="23393" xml_f="23395" txt_i="14705" txt_f="14707">32</offsets></xref><offsets xml_i="23402" xml_f="23403" txt_i="14707" txt_f="14708">]</offsets></sup><offsets xml_i="23409" xml_f="23446" txt_i="14708" txt_f="14745"> CT-1 is a member of the IL-6 family.</offsets><sup><offsets xml_i="23451" xml_f="23452" txt_i="14745" txt_f="14746">[</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="23484" xml_f="23486" txt_i="14746" txt_f="14748">33</offsets></xref><offsets xml_i="23493" xml_f="23494" txt_i="14748" txt_f="14749">]</offsets></sup><offsets xml_i="23500" xml_f="23615" txt_i="14749" txt_f="14864"> Many recent studies have demonstrated that CT-1 is closely associated with the development and progression of CHD.</offsets><sup><offsets xml_i="23620" xml_f="23621" txt_i="14864" txt_f="14865">[</offsets><xref rid="R34" ref-type="bibr"><offsets xml_i="23653" xml_f="23655" txt_i="14865" txt_f="14867">34</offsets></xref><offsets xml_i="23662" xml_f="23663" txt_i="14867" txt_f="14868">]</offsets></sup><offsets xml_i="23669" xml_f="23907" txt_i="14868" txt_f="15106"> Increased CT-1 levels are found in patients with CHD and are associated with disease severity. The present study showed that the combined use of zhibitai and atorvastatin significantly reduced CT-1 and hs-CRP levels in patients with CHD.</offsets></p><p><offsets xml_i="23914" xml_f="24246" txt_i="15107" txt_f="15439">In the present study, there were no significant increases in CK, myopathy, and distinct liver and renal damage in the ZA10 group compared with the A20 or A40 groups, but the number of events was low, preventing any reliable statistical analyses. Nevertheless, previous studies of zhibitai showed a low occurrence of adverse effects.</offsets><sup><offsets xml_i="24251" xml_f="24252" txt_i="15439" txt_f="15440">[</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="24284" xml_f="24286" txt_i="15440" txt_f="15442">24</offsets></xref><offsets xml_i="24293" xml_f="24294" txt_i="15442" txt_f="15443">–</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="24326" xml_f="24328" txt_i="15443" txt_f="15445">26</offsets></xref><offsets xml_i="24335" xml_f="24336" txt_i="15445" txt_f="15446">]</offsets></sup></p><p><offsets xml_i="24349" xml_f="24730" txt_i="15447" txt_f="15828">The present study is not without limitations. Indeed, the sample size was small and from only 2 hospitals. There were no differences among the groups at 8 weeks, and a noninferiority trial should be performed to confirm this equivalence. Further multicenter prospective trials are necessary to reach firm conclusions about the value of zhibitai for the treatment of hyperlipidemia.</offsets></p><p><offsets xml_i="24737" xml_f="24988" txt_i="15829" txt_f="16080">In conclusion, ZA10 in patients with CHD significantly reduced TG, TC, LDL-C, and ApoB levels, as well as the inflammatory cytokines CT-1 and hs-CRP. These changes were similar to those achieved using A40 and A20, but ZA10 led to fewer adverse events.</offsets></p></sec><sec><label><offsets xml_i="25010" xml_f="25011" txt_i="16082" txt_f="16083">5</offsets></label><title><offsets xml_i="25026" xml_f="25037" txt_i="16083" txt_f="16094">Limitations</offsets></title><p><offsets xml_i="25048" xml_f="25508" txt_i="16095" txt_f="16555">As the number of cases in this study is small, the observation time is not long enough, so the data and results are one-sided. This will be improved in future research work. The study is only a 1st sign of possible positive influence of herbal therapy, and further studies in the future are necessary to show positive effects on mortality and cardiac events like myocardial infarction or cardiac sudden death. This is the focus of our study work in the future.</offsets></p></sec><sec><title><offsets xml_i="25530" xml_f="25545" txt_i="16557" txt_f="16572">Acknowledgments</offsets></title><p><offsets xml_i="25556" xml_f="25660" txt_i="16573" txt_f="16677">The authors thank National Natural Science Foundation of China (No. 81672264, 81372117) for the support.</offsets></p></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: CHD = coronary heart disease, ZA10 = zhibitai 480 mg + atorvastatin 10 mg, A20 = atorvastatin 20 mg, A40 = atorvastatin 40 mg, CT-1 = cardiotrophin-1, CRP = C-reactive protein, hs-CRP = high sensitivity-C reactive protein, TC = total cholesterol, LDL = low-density lipoprotein, LDL-C = LDL-cholesterol, ApoB<sub>100</sub> = apolipoprotein B<sub>100</sub>, MI = myocardial infarction, CHM = Chinese herbal medicine.</p></fn><fn fn-type="supported-by"><p>Funding/support: This work was supported by National Natural Science Foundation of China (No. 81672264, 81372117).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leischik</surname><given-names>R</given-names></name><name><surname>Dworrak</surname><given-names>B</given-names></name><name><surname>Strauss</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Plasticity of health</article-title>. <source>Ger J Med [Internet]</source>
<year>2016</year>;<volume>1</volume>:<fpage>1</fpage>–<lpage>7</lpage>.</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leischik</surname><given-names>R</given-names></name><name><surname>Foshag</surname><given-names>P</given-names></name><name><surname>Strauss</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Physical activity, cardiorespiratory fitness and carotid intima thickness: sedentary occupation as risk factor for atherosclerosis and obesity</article-title>. <source>Eur Rev Med Pharmacol Sci</source>
<year>2015</year>;<volume>19</volume>:<fpage>3157</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">26400517</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>SN</given-names></name></person-group>
<article-title>Physical inactivity: the biggest public health problem of the 21st century</article-title>. <source>Br J Sports Med</source>
<year>2009</year>;<volume>43</volume>:<fpage>1</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">19136507</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="book"><collab>World Health Organisation</collab>. <article-title>Global Strategy on Diet, Physical Activity and Health 2004</article-title>; <year>2015</year>
<comment>(15.12.2015)</comment>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menees</surname><given-names>DS</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name></person-group>
<article-title>Evaluation of patients with suspected coronary artery disease</article-title>. <source>Coron Artery Dis</source>
<year>2010</year>;<volume>21</volume>:<fpage>386</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">20555262</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawton</surname><given-names>JS</given-names></name></person-group>
<article-title>Sex and gender differences in coronary artery disease</article-title>. <source>Semin Thorac Cardiovasc Surg</source>
<year>2011</year>;<volume>23</volume>:<fpage>126</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">22041042</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Blankenship</surname><given-names>JC</given-names></name><name><surname>Alexander</surname><given-names>KP</given-names></name><etal></etal></person-group>
<article-title>2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</article-title>. <source>Circulation</source>
<year>2014</year>;<volume>130</volume>:<fpage>1749</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">25070666</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Gardin</surname><given-names>JM</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</article-title>. <source>J Am Coll Cardiol</source>
<year>2012</year>;<volume>60</volume>:<fpage>e44</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">23182125</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><etal></etal></person-group>
<article-title>Heart disease and stroke statistics – 2015 update: a report from the American Heart Association</article-title>. <source>Circulation</source>
<year>2015</year>;<volume>131</volume>:<fpage>e29</fpage>–<lpage>322</lpage>.<pub-id pub-id-type="pmid">25520374</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Rangarajan</surname><given-names>S</given-names></name><name><surname>Teo</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Cardiovascular risk and events in 17 low-, middle-, and high-income countries</article-title>. <source>N Engl J Med</source>
<year>2014</year>;<volume>371</volume>:<fpage>818</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">25162888</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finegold</surname><given-names>JA</given-names></name><name><surname>Asaria</surname><given-names>P</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name></person-group>
<article-title>Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations</article-title>. <source>Int J Cardiol</source>
<year>2013</year>;<volume>168</volume>:<fpage>934</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">23218570</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Istvan</surname><given-names>ES</given-names></name><name><surname>Deisenhofer</surname><given-names>J</given-names></name></person-group>
<article-title>Structural mechanism for statin inhibition of HMG-CoA reductase</article-title>. <source>Science</source>
<year>2001</year>;<volume>292</volume>:<fpage>1160</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">11349148</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>SJ</given-names></name></person-group>
<article-title>Lipid-lowering therapy: who can benefit?</article-title>
<source>Vasc Health Risk Manag</source>
<year>2011</year>;<volume>7</volume>:<fpage>525</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">21915170</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balk</surname><given-names>EM</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Goudas</surname><given-names>LC</given-names></name><etal></etal></person-group>
<article-title>Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review</article-title>. <source>Ann Intern Med</source>
<year>2003</year>;<volume>139</volume>:<fpage>670</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">14568856</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>NJ</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><etal></etal></person-group>
<article-title>2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults</article-title>. <source>A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</source>
<year>2013</year>.</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naci</surname><given-names>H</given-names></name><name><surname>Brugts</surname><given-names>JJ</given-names></name><name><surname>Fleurence</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials</article-title>. <source>Eur J Prev Cardiol</source>
<year>2013</year>;<volume>20</volume>:<fpage>641</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">23447425</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>SP</given-names></name><name><surname>Tsang</surname><given-names>M</given-names></name><name><surname>Wright</surname><given-names>JM</given-names></name></person-group>
<article-title>Lipid lowering efficacy of atorvastatin</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2012</year>;<volume>12</volume>:<fpage>CD008226</fpage>.<pub-id pub-id-type="pmid">23235655</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="book"><collab>Pfizer</collab>. <article-title>Lipitor (atorvastatin clasium) tablets prescribing information</article-title>. <comment>In: Pfizer NY, ed2012</comment>.</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>KK</given-names></name><name><surname>Quon</surname><given-names>MJ</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><etal></etal></person-group>
<article-title>Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients</article-title>. <source>J Am Coll Cardiol</source>
<year>2010</year>;<volume>55</volume>:<fpage>1209</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">20298928</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Seshasai</surname><given-names>SR</given-names></name><name><surname>Erqou</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants</article-title>. <source>Arch Intern Med</source>
<year>2010</year>;<volume>170</volume>:<fpage>1024</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">20585067</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Schmermund</surname><given-names>A</given-names></name><name><surname>Achenbach</surname><given-names>S</given-names></name><name><surname>Budde</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Intensive dose atorvastatin therapy does not attenuate the progression of coronary calcification compared with standard dose atorvastatin therapy over twelve months: a multicenter, randomized, double-blind trial</article-title>. <publisher-name>Circulation; 2005: Lippincott Williams &amp; Wilkins</publisher-name>
<publisher-loc>530 Walnut ST, Philadelphia, PA 19106–3261 USA</publisher-loc>.</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleischer</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>T-T</given-names></name><name><surname>Chiang</surname><given-names>J-H</given-names></name><etal></etal></person-group>
<article-title>Integration of Chinese herbal medicine therapy improves survival of patients with chronic lymphocytic leukemia: a nationwide population-based cohort study</article-title>. <source>Medicine</source>
<year>2016</year>;<volume>95</volume>:<fpage>e3788</fpage>.<pub-id pub-id-type="pmid">27227953</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J-H</given-names></name><name><surname>Chen</surname><given-names>Z-X</given-names></name><name><surname>Zhang</surname><given-names>X-G</given-names></name><etal></etal></person-group>
<article-title>Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: a systematic analysis</article-title>. <source>Medicine</source>
<year>2016</year>;<volume>95</volume>:<fpage>e4904</fpage>.<pub-id pub-id-type="pmid">27749547</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>DY</given-names></name><name><surname>Shu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>QY</given-names></name><etal></etal></person-group>
<article-title>A comparative study of the efficacy and safety Zhibitai and atorvastatin</article-title>. <source>Zhonghua Nei Ke Za Zhi</source>
<year>2010</year>;<volume>49</volume>:<fpage>392</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">20646412</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><etal></etal></person-group>
<article-title>Effectiveness and safety of zhibitai versus atorvastatin for hyperlipidemia: a systematic review</article-title>. <source>Chin J Evidence-Based Med</source>
<year>2013</year>;<volume>13</volume>:<fpage>116</fpage>–<lpage>22</lpage>.</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>DY</given-names></name><name><surname>Shu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>QY</given-names></name><etal></etal></person-group>
<article-title>Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine</article-title>. <source>Atherosclerosis</source>
<year>2010</year>;<volume>211</volume>:<fpage>237</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">20189174</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriszbacher</surname><given-names>I</given-names></name><name><surname>Koppan</surname><given-names>M</given-names></name><name><surname>Bodis</surname><given-names>J</given-names></name></person-group>
<article-title>Inflammation, atherosclerosis, and coronary artery disease</article-title>. <source>N Engl J Med</source>
<year>2005</year>;<volume>353</volume>:<fpage>429</fpage>–<lpage>30</lpage>. <comment>author reply 429–430</comment>.</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benn</surname><given-names>M</given-names></name></person-group>
<article-title>Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review</article-title>. <source>Atherosclerosis</source>
<year>2009</year>;<volume>206</volume>:<fpage>17</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">19200547</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Comparison of lipid levels, hyperlipidemia prevalence and its risk factors between Guangxi Hei Yi Zhuang and Han populations</article-title>. <source>Arch Med Res</source>
<year>2006</year>;<volume>37</volume>:<fpage>787</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">16824940</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soinio</surname><given-names>M</given-names></name><name><surname>Marniemi</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study</article-title>. <source>Diabetes Care</source>
<year>2006</year>;<volume>29</volume>:<fpage>329</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">16443882</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Yonemoto</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<year>2008</year>;<volume>28</volume>:<fpage>1385</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">18403728</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>DH</given-names></name><name><surname>Shin</surname><given-names>HH</given-names></name><etal></etal></person-group>
<article-title>Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension</article-title>. <source>Circ J</source>
<year>2004</year>;<volume>68</volume>:<fpage>297</fpage>–<lpage>303</lpage>.<pub-id pub-id-type="pmid">15056824</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennica</surname><given-names>D</given-names></name><name><surname>King</surname><given-names>KL</given-names></name><name><surname>Shaw</surname><given-names>KJ</given-names></name><etal></etal></person-group>
<article-title>Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>1995</year>;<volume>92</volume>:<fpage>1142</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">7862649</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabro</surname><given-names>P</given-names></name><name><surname>Limongelli</surname><given-names>G</given-names></name><name><surname>Riegler</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Novel insights into the role of cardiotrophin-1 in cardiovascular diseases</article-title>. <source>J Mol Cell Cardiol</source>
<year>2009</year>;<volume>46</volume>:<fpage>142</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">19059413</pub-id></mixed-citation></ref></ref-list></back></article>